Why the study?
The conventional fibrosis-centric paradigm cannot fully explain electrical instability in acute and subacute post-MI phases, and direct human confirmation of the inflammation-electrical remodeling axis in ventricular arrhythmias remains limited, highlighting an unmet need for upstream therapies.
Population
Post-MI patients and animal models with ventricular arrhythmias
Design
Narrative review
Answers are grounded in this paper and cite their sources.
Should not yet change post-MI arrhythmia management; challenges fibrosis-centric paradigm and leaves anti-inflammatory efficacy open pending RCTs.
Ventricular arrhythmias (VA) and sudden cardiac death (SCD) remain leading causes of mortality after myocardial infarction (MI). The conventional fibrosis-centric paradigm explains chronic reentrant VAs but cannot fully account for electrical instability in acute and subacute post-MI phases, highlighting an unmet need for upstream therapies targeting the arrhythmogenic substrate. Accumulating preclinical mechanistic and observational clinical evidence indicates that the inflammatory microenvironment in the infarct border zone may function as a critical upstream driver of electrical remodeling, mediated by neutrophils, macrophages and key pro-inflammatory cytokines (interleukin-1 beta (IL-1β), tumor necrosis factor-α (TNF-α)), constituting an inflammation-electrical remodeling axis that contributes to VA susceptibility across all post-MI stages. While causal relationships have been established in animal models, direct confirmation in human myocardium remains limited. This narrative review synthesizes preclinical and clinical evidence on this axis. It summarizes its spatiotemporal dynamics, four core cellular and molecular mechanisms and the antiarrhythmic potential of diverse anti-inflammatory interventions. We further outline key evidence gaps and translational directions, including precision risk stratification and cell-type-specific targeted delivery. Based on preclinical and preliminary clinical evidence, targeting the inflammation-electrical remodeling axis represents a promising upstream strategy to reduce post-MI SCD by addressing the root causes of electrical instability, though definitive proof of efficacy in humans is pending, and dedicated randomized controlled trials with arrhythmia endpoints are still required for clinical validation.
No takes yet. Share an insight, caveat, or question.
徐文博 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: